Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 25

1.

Patient-Reported Outcomes Are More Important Than Objective Inflammatory Markers for Sick Leave in Biologics-Treated Patients With Rheumatoid Arthritis.

Olofsson T, Söderling JK, Gülfe A, Kristensen LE, Wallman JK.

Arthritis Care Res (Hoboken). 2018 Nov;70(11):1712-1716. doi: 10.1002/acr.23619.

4.

Recurrent fever caused by Candidatus Neoehrlichia mikurensis in a rheumatoid arthritis patient treated with rituximab.

Andréasson K, Jönsson G, Lindell P, Gülfe A, Ingvarsson R, Lindqvist E, Saxne T, Grankvist A, Wennerås C, Marsal J.

Rheumatology (Oxford). 2015 Feb;54(2):369-71. doi: 10.1093/rheumatology/keu441. Epub 2014 Nov 20. No abstract available.

PMID:
25416710
5.

Efficacy and drug survival of anti-tumour necrosis factor-alpha therapies in patients with non-radiographic axial spondyloarthritis: an observational cohort study from Southern Sweden.

Gulfe A, Kapetanovic MC, Kristensen LE.

Scand J Rheumatol. 2014;43(6):493-7. doi: 10.3109/03009742.2014.918173. Epub 2014 Aug 22.

PMID:
25145283
6.
7.

Is swollen to tender joint count ratio a new and useful clinical marker for biologic drug response in rheumatoid arthritis? Results from a Swedish cohort.

Kristensen LE, Bliddal H, Christensen R, Karlsson JA, Gülfe A, Saxne T, Geborek P.

Arthritis Care Res (Hoboken). 2014 Feb;66(2):173-9. doi: 10.1002/acr.22107.

8.

Individualized outcome measures of daily activities are sensitive tools for evaluating hand surgery in rheumatic diseases.

Malcus Johnsson P, Sandqvist G, Sturesson AL, Gulfe A, Kopylov P, Tägil M, Geborek P.

Rheumatology (Oxford). 2012 Dec;51(12):2246-51. doi: 10.1093/rheumatology/kes224. Epub 2012 Sep 1.

PMID:
22942405
9.

National EQ-5D tariffs and quality-adjusted life-year estimation: comparison of UK, US and Danish utilities in south Swedish rheumatoid arthritis patients.

Karlsson JA, Nilsson JÅ, Neovius M, Kristensen LE, Gülfe A, Saxne T, Geborek P.

Ann Rheum Dis. 2011 Dec;70(12):2163-6. doi: 10.1136/ard.2011.153437. Epub 2011 Aug 22.

PMID:
21859684
10.

Utility-based outcomes made easy: the number needed per quality-adjusted life year gained. An observational cohort study of tumor necrosis factor blockade in inflammatory arthritis from Southern Sweden.

Gülfe A, Kristensen LE, Saxne T, Jacobsson LT, Petersson IF, Geborek P.

Arthritis Care Res (Hoboken). 2010 Oct;62(10):1399-406. doi: 10.1002/acr.20235.

11.
12.

Rapid and sustained health utility gain in anti-tumour necrosis factor-treated inflammatory arthritis: observational data during 7 years in southern Sweden.

Gülfe A, Kristensen LE, Saxne T, Jacobsson LT, Petersson IF, Geborek P.

Ann Rheum Dis. 2010 Feb;69(2):352-7. doi: 10.1136/ard.2008.103473. Epub 2009 Mar 11.

PMID:
19282310
13.

Six and 12 weeks treatment response predicts continuation of tumor necrosis factor blockade in rheumatoid arthritis: an observational cohort study from southern Sweden.

Gülfe A, Kristensen LE, Geborek P.

J Rheumatol. 2009 Mar;36(3):517-21. doi: 10.3899/jrheum.080509. Epub 2009 Jan 22.

PMID:
19208596
14.

Predictors of response to anti-TNF therapy according to ACR and EULAR criteria in patients with established RA: results from the South Swedish Arthritis Treatment Group Register.

Kristensen LE, Kapetanovic MC, Gülfe A, Söderlin M, Saxne T, Geborek P.

Rheumatology (Oxford). 2008 Apr;47(4):495-9. doi: 10.1093/rheumatology/ken002. Epub 2008 Mar 3.

PMID:
18316338
15.

Treatment response to a second or third TNF-inhibitor in RA: results from the South Swedish Arthritis Treatment Group Register.

Karlsson JA, Kristensen LE, Kapetanovic MC, Gülfe A, Saxne T, Geborek P.

Rheumatology (Oxford). 2008 Apr;47(4):507-13. doi: 10.1093/rheumatology/ken034. Epub 2008 Feb 27.

PMID:
18304941
16.
17.

Treatment with tumor necrosis factor blockers is associated with a lower incidence of first cardiovascular events in patients with rheumatoid arthritis.

Jacobsson LT, Turesson C, Gülfe A, Kapetanovic MC, Petersson IF, Saxne T, Geborek P.

J Rheumatol. 2005 Jul;32(7):1213-8.

PMID:
15996054
18.

Response criteria for rheumatoid arthritis in clinical practice: how useful are they?

Gülfe A, Geborek P, Saxne T.

Ann Rheum Dis. 2005 Aug;64(8):1186-9. Epub 2005 Mar 10.

19.

Tumour necrosis factor blockers do not increase overall tumour risk in patients with rheumatoid arthritis, but may be associated with an increased risk of lymphomas.

Geborek P, Bladström A, Turesson C, Gulfe A, Petersson IF, Saxne T, Olsson H, Jacobsson LT.

Ann Rheum Dis. 2005 May;64(5):699-703. Epub 2005 Feb 4.

20.
21.

[Diagnostic defaitism worsens the pressure on patients with dyslexia!].

Gülfe A.

Lakartidningen. 1997 Oct 29;94(44):3954. Swedish. No abstract available.

PMID:
9411158
22.

[DAMP and dyslexia--don't listen to the fashionable slogans].

Gülfe A.

Lakartidningen. 1997 Oct 22;94(43):3830. Swedish. No abstract available.

PMID:
9411140
23.

[Severe adverse effect of methotrexate in rheumatoid arthritis. Don't forget security routines in intercurrent disease!].

Gülfe A, Sturfelt G.

Lakartidningen. 1997 May 7;94(19):1811-2. Swedish. No abstract available.

PMID:
9190463
24.

[Need for serious debate on remedial and dyslexia-classes].

Gülfe A.

Lakartidningen. 1995 Oct 18;92(42):3869. Swedish. No abstract available.

PMID:
7564643
25.

[It's important that persons with language disabilities receive stimulative support].

Gülfe A.

Lakartidningen. 1994 Mar 9;91(10):925. Swedish. No abstract available.

PMID:
8139307

Supplemental Content

Support Center